Prudent Drug Discovery Company
Low market cap ( appox £13m at time of writing ).
Issues shares very rarely ( last placing nearly four years ago ).
Has material interest in its work from larger partners ( Pharmaxis ).
Sold interest in LOXL2 programme for £5m to Pharmaxis in December.
Pharmaxis continues to fund and develop LOXL2 inhibitors and Synairgen retains...
Star Combo Pharma has just started trading last week. It has a good run up to above $2. I believe this is Wave 1 of Elliot. The price has dropped a bit at writing and if I am not wrong, corrective wave 2 will probably hit between 0.5 to 0.618 in the next few days. If i were to trade, i would look for entry below $1.30 between 0.5 to 0.618 fibonacci. At writing,...
What a tumultuous market.
Celgene reports earnings on 5/4. Earnings play aside, are traders and investors rotating into or out of pharmaceuticals?
The market doesn't know what to do with itself right now. With a Fed meeting taking place over the next couple days, Caterpillar's CFO claiming we've seen a "high water mark" with Q1 earnings, rate concerns,...
Good opportunity to buy a potential 3 wave in development with a natural stop loss at immediately prior low. One of the few bullish charts I've seen in the stock market recently.
MY OPINION: Jumped into SNSS at this low signal of 4.24. This drop in share price occurred after recent earnings report on March 8th. This is a psychological pitfall, expecting shares to jump back between the middle and bottom Bands by mid week.
THE FACTS:
The company reported $0.21 earnings per share for the quarter
Sunesis Pharmaceuticals has a 52 week low...
Relative strength index (RSI-14) for Eyegate Pharmaceuticals, Inc. (EYEG) is at 35.36.
Stock price escalated 6.42% to finalize at $0.58 throughout previous buying and selling session.
EYEG is trading -79.65% downward from the 52-week high mark and 17.24% above from the fifty two-week low mark.
Lets see what next week will bring!
After a recent check, the 14-day RSIfor China Pharma Holdings (CPHI) is currently at 65.41, the 7-day stands at 78.81, and the 3-day is sitting at 94.30.Many professionals agree that realizing a loss is just as important as picking a winner, so I've also included a potential loss area to point out my opinion of when to abort...
SRNE looks bullish.
So far this has been climbing up my original projections, however, exceeding my highest highs as this stock continues to display an extension of wave 3.
IF in fact this current cycle of waves is only a WAVE 3 (per Elliot Wave analysis and rules), then this may reach and exceed the $21.00 mark!
So here are the targets if this count is...
I love it when fundamentals and technicals line up together. I am in general very bullish towards cloud-software companies, thats the future, especially when they have a footing in the pharma industry like veeva. This is a huge market and growing strongly year by year. The chart is a textbook bull flag. I am expecting a move into 80$ over the coming months....
New and innovative product. Quell's proven technology is 5x more powerful on average than other over-the-counter pain relief devices. It is discreet and completely wearable to enable pain relief when your patients need it.
Increased quarterly earnings growth.
Low floater
Resistance at at 3.00 range due to the preferred shares being exercisible at...
FDA Grants INSYS Therapeutics ‘Fast Track’ Designation for Cannabidiol (CBD) Oral Solution as
INSYS Therapeutics, Inc. (NASDAQ:INSY), announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s cannabidiol (CBD) oral solution for the treatment of Prader-Willi syndrome, a rare and complex genetic disorder...
DMPI (Delmar Pharma) has increased about 40% on a bullish break out. A bull flag has formed after a break out from a large wedge pattern with good volume. Looks like a strong bottom at .80. News was released yesterday that their drug VAL is being "fast tracked" this brings grant money payed by the govt. Looking for a continued bullish trend and news coming from...
Despite the recent company's efforts to reduce its debit, from a technical point of view, I would be neutral with Teva until we will see a cross-over between slow 200d and fast 50d moving average on a daily chart pattern. For those who are aggressives MACD is still positive but keep in mind the resistence at 19.33 first and 20 after. Exhaustion gap betweeen 16 and...
VRX after the correction largly expected, yesterday as demostrated a strong bullish counterattack closing the session slightly less than the short entry recovering mostly 100%. The pattern therefore shows clearly the uptrend line in place. Investors are considering a Q4 better than Q3 looking for new confirmation about debit reduction, so I expect price will move...
We reached 17.70 dollars and than a fast pullback as it was for the day before. Important resistence near 18 with possible retracement on the ascendent trendline first and the second dotted trendline after. Personally I sold it at 17 in order to see what it will look like next weeks. RSI overbought, MACD still positive.
